EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade

Imran Khan, Aida Rodriguez-Brotons, Anukana Bhattacharjee, Vladimir Bezrookove, Altaf Dar, David De Semir, Mehdi Nosrati, Ryan Ice, Liliana Soroceanu, Stanley P Leong, Kevin B Kim, Yihui Shi und 8 weitere

Journal of Clinical Investigation · 16.09.2025 · 135 (18)

DOI: 10.1172/jci185220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 10.07.2025. Verfasst von Imran Khan und 19 weiteren Autor:innen. Beteiligte Einrichtung: California Pacific Medical Center (CPMC) Research Institute, San Francisco, California, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Melanoma, Drug Resistance, Neoplasm, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Few effective therapeutic options exist after progression on immune checkpoint blockade (ICB) for melanoma. Here, we utilized a platform incorporating transcriptomic profiling, high-throughput drug screening, and murine models to demonstrate the preclinical efficacy of several combinatorial regimens against ICB-resistant melanoma. Transcriptomic analysis of ICB-resistant melanomas demonstrated activation of several targetable pathways. High-throughput drug screening targeting these pathways identified several effective combinations in ICB-resistant patient-derived xenograft models. The combination of cobimetinib and regorafenib (termed Cobi+Reg) emerged as a particularly promising regimen, with efficacy against distinct molecular melanoma subtypes and after progression on ICB in immunocompetent models. Transcriptomic and spatial analysis of Cobi+Reg–treated tumors demonstrated upregulation of antigen presentation machinery, with concomitantly increased activated T cell infiltration. Combining Cobi+Reg with ICB was superior to either modality in vivo. This analytical platform exploits the biology of ICB-resistant melanoma to identify therapeutic vulnerabilities, resulting in the identification of drug combinations that form the basis for rational clinical trial design in the setting of advanced melanoma resistant to ICB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsMelanomaDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsSkin NeoplasmsAnimalsMiceHumansPyridinesPhenylurea CompoundsAzetidinesPiperidinesCell Line, TumorXenograft Model Antitumor AssaysFemale

Stichwörter der Autor:innen

Cancer immunotherapyDermatologyExpression profilingMelanomaOncology

Substanzen

Immune Checkpoint InhibitorsPyridinesPhenylurea CompoundscobimetinibAzetidinesregorafenibPiperidines

Autor:innen und Institutionen

  • California Pacific Medical Center (CPMC) Research Institute, San Francisco, California, USA.
  • Center for Melanoma Research and Treatment, CPMC, San Francisco, California, USA.
  • Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Dermatology, University of California San Francisco, San Francisco, California, USA.
  • Melanoma Program, Division of Medical Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • Department of Dermatology, Yale University, New Haven, Connecticut, USA.

Förderung

  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Khan, I., Rodriguez-Brotons, A., Bhattacharjee, A., Bezrookove, V., Dar, A., De Semir, D., Nosrati, M., Ice, R., Soroceanu, L., Leong, S. P., Kim, K. B., Shi, Y., Cleaver, J. E., Miller, J. R., Desprez, P. Y., Kirkwood, J. M., Bosenberg, M., Salomonis, N., McAllister, S., & Kashani-Sabet, M. (2025). Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade. Journal of Clinical Investigation, 135(18). https://doi.org/10.1172/jci185220

Vancouver

Khan I, Rodriguez-Brotons A, Bhattacharjee A, Bezrookove V, Dar A, De Semir D, et al. Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade. Journal of Clinical Investigation. 2025;135(18). doi:10.1172/jci185220

BibTeX
@article{Khan2025,
  author = {Khan, Imran and Rodriguez-Brotons, Aida and Bhattacharjee, Anukana and Bezrookove, Vladimir and Dar, Altaf and De Semir, David and Nosrati, Mehdi and Ice, Ryan and Soroceanu, Liliana and Leong, Stanley P and Kim, Kevin B and Shi, Yihui and Cleaver, James E and Miller, James R and Desprez, Pierre-Yves and Kirkwood, John M and Bosenberg, Marcus and Salomonis, Nathan and McAllister, Sean and Kashani-Sabet, Mohammed},
  title = {Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {18},
  doi = {10.1172/jci185220}
}
Kostenlos starten →